发明名称 |
BQC-G, a tumor-selective anti-cancer prodrug |
摘要 |
The invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug (BQC-G) of a potent anticancer camptothecin derivative 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G was over 4000 times more water soluble than BQC, displayed good stability in human plasma and was an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. BQC-G was about 30 times less toxic than BQC, but was as toxic as BQC after hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G displayed lower cytotoxicity (IC50=1080 nM) but could be activated by β-glucuronidase to display potent activity (IC50=13.3 nM). |
申请公布号 |
US9353140(B2) |
申请公布日期 |
2016.05.31 |
申请号 |
US201013512255 |
申请日期 |
2010.11.24 |
申请人 |
Academia Sinica |
发明人 |
Prijovic Zeljko M.;Leu Yu-Lin;Roffler Steve R. |
分类号 |
A61K31/706;C07H15/26;A61P35/00;C07H15/203 |
主分类号 |
A61K31/706 |
代理机构 |
Drinker Biddle & Reath LLP |
代理人 |
Drinker Biddle & Reath LLP |
主权项 |
1. A compound according to the formula I, below: wherein R is a glucuronide linked via an immolative spacer, or a pharmaceutically acceptable salt thereof. |
地址 |
Taipei TW |